Arovella Therapeutics : Proposed issue of securities - ALA

Proposed issue of securities

Announcement Summary

For personal use only

Entity name

AROVELLA THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement 17/3/2022

The Proposed issue is:

A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
		Maximum Number of
ASX +security code	+Security description	+securities to be issued
ALAAA	OPTION EXPIRING VARIOUS DATES EX VARIOUS	2,500,000
	PRICES
ALA	ORDINARY FULLY PAID	631,578

Proposed +issue date 31/3/2022

Refer to next page for full details of the announcement

Proposed issue of securities

1 / 6

Proposed issue of securities

Part 1 - Entity and announcement details

For personal use only

1.1 Name of +Entity

AROVELLA THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2	Registered Number Type	Registration Number
ABN	35090987250
1.3	ASX issuer code
ALA

1. The announcement is New announcement
2. Date of this announcement

17/3/2022

1.6 The Proposed issue is:

A placement or other type of issue

Proposed issue of securities

2 / 6

Proposed issue of securities

Part 7 - Details of proposed placement or other issue

only
	Part 7A - Conditions
		7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other
		type of issue can proceed on an unconditional basis?
use	No
	Part 7B - Issue details
		Is the proposed security a 'New	Will the proposed issue of this
		class' (+securities in a class that is	+security include an offer of
		not yet quoted or recorded by ASX)	attaching +securities?
personal	or an 'Existing class' (additional	No
securities in a class that is already
consideration?
		quoted or recorded by ASX)?
		Existing class
	Details of +securities proposed to be issued
		ASX +security code and description
		ALA : ORDINARY FULLY PAID
		Number of +securities proposed to be issued
		631,578
		Offer price details
		Are the +securities proposed to be issued being issued for a cash
For	Yes
In what currency is the cash	What is the issue price per
		consideration being paid?	+security?
		AUD - Australian Dollar	AUD 0.03800

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Proposed issue of securities

3 / 6

Proposed issue of securities

		Is the proposed security a 'New	Will the proposed issue of this
		class' (+securities in a class that is	+security include an offer of
		not yet quoted or recorded by ASX)	attaching +securities?
		or an 'Existing class' (additional	No
only	securities in a class that is already
quoted or recorded by ASX)?
Existing class
	Details of +securities proposed to be issued
		ASX +security code and description
		ALAAA : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
use	Number of +securities proposed to be issued
2,500,000
		Offer price details
		Are the +securities proposed to be issued being issued for a cash
		consideration?
personal	No

Please describe the consideration being provided for the +securities

The unlisted options will be issued for the provision of corporate advisory service in lieu of cash.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities 0.020400

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C - Timetable

For

7C.1 Proposed +issue date

31/3/2022

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No

Proposed issue of securities

4 / 6

use only

Proposed issue of securities

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

3,131,578

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No

Part 7E - Fees and expenses

personal

7E.1 Will there be a lead manager or broker to the proposed issue? No

7E.2 Is the proposed issue to be underwritten? No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Pa t 7F - Further Information
For	7F.01 The purpose(s) for which the entity is issuing the securities

• Placement to fund manufacturing of components for the CAR19-iNKT cell therapy, to perform preclinical studies and for working capital purpose
• To issue unlisted options for the provision of corporate advisory service in lieu of cash

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

Proposed issue of securities

5 / 6